Stock listing
DWTX Stock Price, News, Filings & Events — Dogwood Therapeutics, Inc.
Selected listing: DWTX · NASDAQ · USD · US
This page tracks Dogwood Therapeutics, Inc.'s DWTX:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following DWTX:NASDAQ. DWTX:NASDAQ is the stock-level entry point for investors researching Dogwood Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Dogwood Therapeutics, Inc. (DWTX) is a public company based in the United States with a market capitalization of approximately $50.4 million. The company is focused on developing innovative therapeutic solutions. As a publicly traded entity, it is listed on the relevant stock exchanges in America.
- Ticker
- DWTX:NASDAQ
- Asset type
- Stock
- Market cap
- $65.9M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
Dogwood Therapeutics, Inc. DWTX:NASDAQ stock context
This page tracks Dogwood Therapeutics, Inc.'s DWTX:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following DWTX:NASDAQ. DWTX:NASDAQ is the stock-level entry point for investors researching Dogwood Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Dogwood Therapeutics, Inc. (DWTX) is a public company based in the United States with a market capitalization of approximately $50.4 million. The company is focused on developing innovative therapeutic solutions. As a publicly traded entity, it is listed on the relevant stock exchanges in America.
Latest news from Dogwood Therapeutics, Inc.
Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
September 14, 2026
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
August 17, 2026
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
August 13, 2026
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
July 20, 2026
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
June 30, 2026
Dogwood Therapeutics, Inc. earnings calls
Virios Therapeutics, Inc. (VIRI) Q2 2024 Earnings Call
August 7, 2024 · Replay with transcript and chapters
Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call
May 9, 2024 · Replay with transcript and chapters
Virios Therapeutics, Inc. (VIRI) Q3 2023 Earnings Call
November 13, 2023 · Replay with transcript and chapters
Virios Therapeutics, Inc. (VIRI) Q2 2023 Earnings Call
August 10, 2023 · Replay with transcript and chapters
Virios Therapeutics, Inc. (VIRI) Q3 2022 Earnings Call
November 14, 2022 · Replay with transcript and chapters
Virios Therapeutics, Inc. (VIRI) Q2 2022 Earnings Call
August 11, 2022 · Replay with transcript and chapters
Research Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for DWTX:NASDAQ.
Dogwood Therapeutics, Inc. company profile
View the public company page for Dogwood Therapeutics, Inc. on 6ix.
Dogwood Therapeutics, Inc. news
Read company news and market updates connected to Dogwood Therapeutics, Inc..
Dogwood Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Dogwood Therapeutics, Inc..